ArticleCancer reports (Hoboken, N.J.)2025
Efficacy and Safety of Combination Androgen-Receptor Signaling Inhibitors, Denosumab, and Local Radiotherapy for Poly-Metastatic Prostate Cancer.
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy and Safety of Combination Androgen-Receptor Signaling Inhibitors, Denosumab, and Local Radiotherapy for Poly-Metastatic Prostate Cancer.Cancer reports (Hoboken, N.J.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe Treatment of Metastatic Castration-Sensitive Prostate Cancer (mCSPC) has dramatically changed over the past decade. To improve oncological outcomes, pharmacological treatments have evolved to include two-or three-drug combinations, and the efficacy of local radiation therapy (LRT) at the prostate combined with denosumab chemotherapy has been discussed.
aimsThis study aimed to provide an interim evaluation of the combination of androgen receptor signaling inhibitors denosumab, LRT, and metastasis-directed therapy (MDT) for prostate cancer with multiple bone metastases (poly-PCa).
methodsWe are currently conducting a single-arm prospective study to evaluate the combination of enzalutamide, LRT, denosumab, and MDT in terms of improving oncological outcomes in patients with poly-PCa. The primary endpoints were prostate-specific antigen (PSA)-based progression-free survival (PFS) and radiographic PFS (rPFS).
resultsTwenty patients have been enrolled in the study to date. The median follow-up period thus far is 18.0 months (interquartile range, 14.0-25.8 months). The 1-year PFS rate is 84.4% at present, and the rPFS rate is 100%. Seventeen patients (85.0%) achieved a PSA reduction of ≥ 90% versus their baseline values at enrollment, and 10 (50.0%) maintained PSA levels of < 0.2 ng/mL.
conclusionThis treatment strategy is expected to improve the oncological outcomes of patients with poly-PCa. A more comprehensive report of this study with more patients and a longer observation period is forthcoming.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.